Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform

Go back to Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform

Regeneron Reports First Quarter 2016 Financial and Operating Results

May 5, 2016 6:30 AM EDT

TARRYTOWN, N.Y., May 5, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2016 and provided a business update.

Financial Highlights

($ in millions, except per share data)

... More